Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Covington
Colorcon
Medtronic
Express Scripts
AstraZeneca

Generated: September 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LABETALOL HYDROCHLORIDE

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Clinical Trials for Labetalol Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000291 Effects of Labetalol on Human Cocaine Use - 8 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine.
NCT00000291 Effects of Labetalol on Human Cocaine Use - 8 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine the effect of labetalol treatment on the subjective and physiological effects of cocaine.
NCT00000297 Effects of Labetalol on Nicotine Administration in Humans - 14 Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine
NCT00000297 Effects of Labetalol on Nicotine Administration in Humans - 14 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00194974 Treatment Targets for Chronic Hypertension in Pregnancy Unknown status Weill Medical College of Cornell University Phase 1/Phase 2 This project is a clinical study of women with high blood pressure who become pregnant. Preeclampsia is a syndrome developing at the end of a pregnancy characterized by an abrupt rise in blood pressure (BP), blood clotting and kidney dysfunction, and may result in premature delivery, infant death, and maternal bleeding, kidney failure and stroke. The goal is to determine whether lowering blood pressure to a normal pressure of 120/80 is associated with a lower incidence of preeclampsia. Women who are completely healthy have a 5% chance of developing preeclampsia, however women with preexisting high blood pressure have a 25% chance of this complication. Several studies, including our own suggest that higher blood pressure early in pregnancy (<20 weeks) is associated with an even higher risk of preeclampsia. Currently we, the researchers at Weill Medical College of Cornell University, do not know how to treat women with high blood pressure and/or kidney disease during pregnancy. Keeping the BP in the normal range may be beneficial to the mother. On the other hand, we are not sure if the blood pressure lowering or the medications may or may not have adverse effects for the baby. Different trials to answer this question have been performed with no clear conclusions. Because of these uncertainties, we propose to compare two different strategies for treating women with high BP who become pregnant. We will treat half the women with BP medications to normalize BP (120-130/80 mm Hg) (experimental group) and the other half with the goal of keeping the BP slightly higher (140-150/90-100 mm Hg)(standard therapy group). We will determine which approach results in healthier pregnancies, and lower incidence of preeclampsia. Reducing the incidence of preeclampsia would be of significant benefit to both mothers and babies.
>Trial ID >Title >Status >Phase >Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Labetalol Hydrochloride

Condition Name

Condition Name for Labetalol Hydrochloride
Intervention Trials
Hypertension 5
Preeclampsia 4
Hypertension in Pregnancy 3
Brain Tumor 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Labetalol Hydrochloride
Intervention Trials
Hypertension 14
Pre-Eclampsia 14
Hypertension, Pregnancy-Induced 8
Eclampsia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Labetalol Hydrochloride

Trials by Country

Trials by Country for Labetalol Hydrochloride
Location Trials
United States 27
Canada 6
Egypt 5
Pakistan 2
Saudi Arabia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Labetalol Hydrochloride
Location Trials
New York 7
California 4
Texas 2
Tennessee 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Labetalol Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Labetalol Hydrochloride
Clinical Trial Phase Trials
Phase 4 16
Phase 3 5
Phase 2/Phase 3 3
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Labetalol Hydrochloride
Clinical Trial Phase Trials
Recruiting 15
Completed 15
Not yet recruiting 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Labetalol Hydrochloride

Sponsor Name

Sponsor Name for Labetalol Hydrochloride
Sponsor Trials
Mansoura University 3
University of Alberta 3
Cedars-Sinai Medical Center 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Labetalol Hydrochloride
Sponsor Trials
Other 52
Industry 3
U.S. Fed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Cipla
US Department of Justice
Colorcon
Moodys
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.